Biotech pain con­tin­ues as Ver­sant, MPM gene ther­a­py start­up calls it quits

A gene ther­a­py start­up backed by two key bio­phar­mas and two pre­mier biotech VC firms has ceased op­er­a­tions.

Cal­i­for­nia biotech Co­da Bio­ther­a­peu­tics shut down re­cent­ly, in­vestors Ver­sant Ven­tures and MPM Cap­i­tal con­firmed to End­points News Tues­day night, de­clin­ing to pro­vide fur­ther de­tails. The up­start had pre­sent­ed pre­clin­i­cal da­ta on its pro­gram for fo­cal epilep­sy last sum­mer but had not pro­vid­ed an up­date since then. MPM re­moved Co­da from its port­fo­lio page in re­cent weeks, per in­ter­net archives, and the biotech’s LinkedIn page has been wiped.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN